No Pharma Money
News & Reports
News January 28, 2019

The Week in Review in Prescription Drug Pricing

By P4ADNow Team

It’s drug pricing palooza!
 
Welcome to the week in review in prescription drug pricing.

1.  LOL Pfizer

  • Pfizer spun its January price hikes as impacting an itsy bitsy portion of its drugs. Too bad the 41 drugs it hiked represent half the pharma giant’s revenue. — (Axios)

 
2. Johnny Depp would be proud. 

  • PhRMA is running ghost ships now. — (WaPo)

 
3. All the hearings

  • The Republican-controlled Senate and Democratic-controlled House are kicking off 2019 by lighting up out-of-control drug pricing with Senate Finance and House Oversight committee hearings Tuesday.— (The Hill)

4. It’s a thing. A 2020 thing.
Potential presidential candidates are staking claims in the drug pricing debate. Smart move,

since 80 percent of the public wants our elected leaders to lower drug prices. — (KHN)

5. Highly Illogical

  • The drug lobby’s arguments against holding down prices in Medicare Part B just don’t add up. — (STAT)

Stay Connected

Stay informed about the latest campaigns, policy developments, and ways to help lower prescription drug prices.